News
PHAT
9.17
+7.76%
0.66
Weekly Report: what happened at PHAT last week (0803-0807)?
Weekly Report · 2d ago
Weekly Report: what happened at PHAT last week (0727-0731)?
Weekly Report · 08/03 09:43
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
Barchart · 08/03 09:07
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough
Simply Wall St · 07/31 23:28
Phathom Pharmaceuticals Price Target Cut to $22.00/Share From $25.00 by Guggenheim
Dow Jones · 07/31 14:22
Phathom Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones · 07/31 14:22
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Benzinga · 07/31 14:12
Phathom Pharmaceuticals price target lowered to $20 from $22 at Craig-Hallum
TipRanks · 07/31 13:31
Phathom Pharmaceuticals price target lowered to $22 from $25 at Guggenheim
TipRanks · 07/31 11:01
Phathom Pharmaceuticals: Strong VOQUEZNA Momentum and Pipeline Progress Support Maintained $26 Price Target and Buy Rating
TipRanks · 07/31 10:27
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Dow Jones · 07/31 10:18
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Benzinga · 07/31 10:07
Phathom Pharmaceuticals Is Maintained at Buy by Needham
Dow Jones · 07/30 19:35
Phathom Pharmaceuticals Price Target Cut to $22.00/Share From $28.00 by Needham
Dow Jones · 07/30 19:35
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Benzinga · 07/30 19:25
Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham
TipRanks · 07/30 19:20
Analysts’ Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)
TipRanks · 07/30 18:10
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
Barchart · 07/30 16:34
Phathom Pharmaceuticals Down Over 19%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk
Dow Jones · 07/30 16:32
Midday Fly By: Microsoft reports sharp Q4 beat, Meta misses on earnings
TipRanks · 07/30 16:16
More
Webull provides a variety of real-time PHAT stock news. You can receive the latest news about Phathom Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.